Pfizer Launches Final Study for COVID Drug that’s Suspiciously Similar to ‘Horse Paste’

By Zero Hedge
Global Research, October 02, 2021
Zero Hedge 28 September 2021
Region:
Theme:

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

Visit and follow us on Instagram at @crg_globalresearch.

***

 

Another piece US anti-Ivermectin puzzle may have emerged. In late September, Pfizer announced that it’s launching an accelerated Phase 2/3 trial for a COVID prophylactic pill designed to ward off COVID in those may have come in contact with the disease.

Coincidentally (or not), Pfizer’s drug shares at least one mechanism of action as Ivermectin – an anti-parasitic used in humans for decades, which functions as a protease inhibitor against Covid-19, which researchers speculate “could be the biophysical basis behind its antiviral efficiency.”

Lo and behold, Pfizer’s new drug – which some have jokingly dubbed “Pfizermectin,” is described by the pharmaceutical giant as a “potent protease inhibitor.”

As Zero Hedge readers might recognize, that’s exactly what ivermectin, the prophylactic used for a number of reasons in both humans and animals, does. And unlike Pfizer’s experimental drug, ivermectin already may have saved hundreds of thousands of lives from India to Brazil.

We aren’t the only ones to have put this together, as twitter users have commented on the similarities. The timing – which coincides with the whole “horse dewormer” smear campaign – just seems odd.

The similarity between Pfizer’s upcoming offering and Ivermectin has not gone unnoticed.

But Pfizer, Moderna and their executives have already shown the world with their actions that they see COVID as “manna from heaven” – to quote legendary defense attorney Johnny Cochran –  a new ‘profit center’ that will keep shareholders in butter brickle, especially since the companies have quietly raised prices on their vaccines.

But since a large portion of the American market has rejected the vaccines, Pfizer needs another medication that can be used to treat them as well (otherwise, the company is missing out on nearly one-third of the American market).

According to Reuters, Pfizer said on Monday it has “started a large study testing its investigational oral antiviral drug for the prevention of COVID-19 infection among those who have been exposed to the virus.”

Pfizer isn’t the only drugmaker hoping to develop a prophylactic treatment for COVID exposure (especially since variants raise the possibility that vaccinations just might not be enough). Merck and Swiss rival Roche have been racing to develop an easy-to-administer antiviral pill of their own – so the clock is ticking for Pfizer.

Reuters explains that the mid-to-late-stage study will test the Pfizer drug’s – known as PF-07321332 ability to prevent COVID symptoms in up to 2,660 healthy adult participants aged 18 and older who live in the same household as an individual with a confirmed symptomatic COVID infection.

The drug, designed to block the activity of a key enzyme needed for the coronavirus to multiply inside the human body, will be administered along with a low dose of ritonavir, an older medication widely used in combination treatments for HIV infection.

At present, Gilead’s much-hyped but not-all-that-effective IV drug remdesivir is the only approved antiviral treatment for COVID in the US. Several antibody cocktails have also been widely tested and trials are ongoing – including Merck and partner Ridgeback Biotherapeutics, which recently launched a late-stage trial for experimental COVID prophylactic, molnupiravir.

In the mean time, concerned citizens should keep an eye out for any new information about Ivermectin – if you can find it.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is from Zero Hedge
Articles by: Zero Hedge

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [email protected]

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [email protected]